PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. MRSN, ACRV, KPTI, KALA, ELYM, STTK, PEPG, XLO, RANI, and LTRNShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Mersana Therapeutics (MRSN), Acrivon Therapeutics (ACRV), Karyopharm Therapeutics (KPTI), KALA BIO (KALA), Eliem Therapeutics (ELYM), Shattuck Labs (STTK), PepGen (PEPG), Xilio Therapeutics (XLO), Rani Therapeutics (RANI), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Mersana Therapeutics Acrivon Therapeutics Karyopharm Therapeutics KALA BIO Eliem Therapeutics Shattuck Labs PepGen Xilio Therapeutics Rani Therapeutics Lantern Pharma Mersana Therapeutics (NASDAQ:MRSN) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership. Do insiders and institutionals hold more shares of MRSN or PHXM? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer MRSN or PHXM? Mersana Therapeutics currently has a consensus price target of $5.20, indicating a potential upside of 1,494.60%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mersana Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MRSN or PHXM? In the previous week, Mersana Therapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Mersana Therapeutics and 0 mentions for PHAXIAM Therapeutics. Mersana Therapeutics' average media sentiment score of 1.87 beat PHAXIAM Therapeutics' score of 0.00 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mersana Therapeutics Very Positive PHAXIAM Therapeutics Neutral Is MRSN or PHXM more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. PHAXIAM Therapeutics' return on equity of 0.00% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-217.63% -990.16% -48.87% PHAXIAM Therapeutics N/A N/A N/A Which has more volatility & risk, MRSN or PHXM? Mersana Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Which has preferable valuation & earnings, MRSN or PHXM? PHAXIAM Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$34.01M1.20-$69.19M-$0.59-0.55PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A SummaryMersana Therapeutics beats PHAXIAM Therapeutics on 9 of the 14 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$130.89M$5.61B$9.30BDividend YieldN/A3.74%4.23%4.03%P/E RatioN/A3.6028.5219.58Price / SalesN/A4,273.29426.1793.37Price / CashN/A13.1936.0257.93Price / Book0.3941.918.135.54Net Income-$240K-$92.15M$3.24B$257.73M7 Day PerformanceN/A1.00%0.20%-0.08%1 Month PerformanceN/A5.35%5.98%8.09%1 Year PerformanceN/A161.01%26.15%13.02% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049MRSNMersana Therapeutics4.1532 of 5 stars$0.38+12.7%$5.20+1,268.4%-84.3%$42.03M$40.50M-0.64150Positive NewsHigh Trading VolumeACRVAcrivon Therapeutics3.7384 of 5 stars$1.35+0.7%$17.71+1,212.2%-82.9%$42.02MN/A-0.6158Positive NewsKPTIKaryopharm Therapeutics3.9673 of 5 stars$5.00+4.0%$43.20+764.0%-70.8%$41.56M$145.24M-0.38380KALAKALA BIO3.897 of 5 stars$6.90+9.5%$13.50+95.7%-28.1%$40.65M$3.89M-0.8430High Trading VolumeELYMEliem TherapeuticsN/A$1.35+7.1%N/A-79.7%$40.17MN/A-2.559STTKShattuck Labs3.7027 of 5 stars$0.77-6.0%$7.50+868.6%-82.8%$39.47M$5.72M-0.56100News CoveragePositive NewsPEPGPepGen3.0862 of 5 stars$1.25+5.9%$7.67+513.3%-92.5%$38.61MN/A-0.4030XLOXilio Therapeutics2.8967 of 5 stars$0.74+1.3%$4.00+437.7%-29.4%$38.03M$9.27M-0.8970RANIRani Therapeutics1.9902 of 5 stars$0.66-0.1%$7.33+1,010.6%-89.2%$37.99M$1.20M-0.67110News CoverageGap DownLTRNLantern Pharma2.9889 of 5 stars$3.51+3.5%$25.00+612.3%-13.6%$36.56MN/A-1.9120News Coverage Related Companies and Tools Related Companies Mersana Therapeutics Competitors Acrivon Therapeutics Competitors Karyopharm Therapeutics Competitors KALA BIO Competitors Eliem Therapeutics Competitors Shattuck Labs Competitors PepGen Competitors Xilio Therapeutics Competitors Rani Therapeutics Competitors Lantern Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts